CAMBRIDGE, Massachusetts, August 19, 2026, 23:10 EDT — Moderna’s stock soared nearly three times higher following a positive outcome in its melanoma program, but analysts caution the company’s market valuation remains ahead of its actual sales.
Shares of Moderna, Inc. NASDAQ:MRNA finished Wednesday at $174.38, surging 177%, following positive results from a Phase 3 melanoma trial that achieved two primary endpoints. The outcome boosted Moderna’s market capitalization by roughly $44 billion during the session.
The increase in price was significantly greater than the value of a single melanoma launch. Barclays had projected annual melanoma sales to reach about $3 billion by 2035. The rise in value on Wednesday was nearly 15 times that amount.
| Market snapshot | August 19 close or move | Investor read-through |
|---|---|---|
| Moderna NASDAQ:MRNA | $174.38; +177% | Biggest re-rating; roughly $44 billion in value created |
| Merck & Co. NYSE:MRK | $152.20; +12.6% | All-time closing high; possible Keytruda franchise extension |
| BioNTech SE NASDAQ:BNTX | About +22% | Benefits seen for additional mRNA cancer platforms |
| Nasdaq Biotechnology Index | +5.2% | Confirmed sector validation trend |
Intismeran autogene is developed using mutations unique to each patient’s tumor. Moderna and Merck use it alongside Keytruda, Merck’s checkpoint inhibitor. The Phase 3 study involved 1,137 patients following surgery for stage IIB-IV melanoma.
| INTerpath-001 measure | Interim outcome | What remains unknown |
|---|---|---|
| Recurrence-free survival | Marked and statistically meaningful benefit | Hazard ratio and absolute figures not published |
| Distant metastasis-free survival | Marked and statistically meaningful benefit | Full event numbers not published |
| Overall survival | No data available | Unclear if overall lifespan improves |
| Safety | No new safety risks observed | Comprehensive safety data pending full report |
The companies have yet to disclose hazard ratios or the absolute rates of recurrence. They intend to share complete findings during an upcoming international medical conference. Data on overall survival is also unavailable.
The previous Phase 2b trial serves as a reference point, not a projection for Phase 3 outcomes. At the five-year mark, the combination demonstrated a 49% reduction in the risk of recurrence or death. The risk of distant metastasis or death was lowered by 59%.
| Repricing check | Verified input | Calculation |
|---|---|---|
| Difference in value compared to 2035 melanoma sales forecast | $44 billion versus $3 billion | 14.7 times |
| Last close against pre-readout consensus estimate | $174.38 versus $50.84 | 243% higher |
| Last close versus top published target | $174.38 versus $77 | 126% higher |
| Weekly change from August 12 | $63.67 to $174.38 | 174% increase |
The main concern for investors is the gap. Securing melanoma approval may restart revenue expansion. However, Wednesday’s closing price also reflects expectations for lung, bladder, and kidney projects that are still in clinical trials.
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, described the outcome as a turning point for immunotherapy. “The positive hit here leads us into truly this next phase in immunotherapy,” she said. Reuters
| Pre-readout analyst recommendation | Rating | Target | Date |
|---|---|---|---|
| Piper Sandler | Overweight | $77 | August 3, 2026 |
| Goldman Sachs | Neutral | $67 | July 21, 2026 |
| Citigroup | Neutral | $60 | August 3, 2026 |
| RBC Capital | Sector Perform | $45 | July 7, 2026 |
| Wolfe Research | Underperform | $25 | July 20, 2026 |
Previous price targets now serve as weak valuation references. The gap between these targets and the closing price highlights the limited oncology value reflected in existing models. Analyst updates are expected as an initial test this week.
| Moderna financial baseline | Q2 2026 or guidance |
|---|---|
| Quarterly revenue | $145 million |
| GAAP net loss | Approximately $0.8 billion |
| GAAP loss per share | $1.97 |
| Expected year-end cash | Between $4.7 billion and $5.2 billion |
| 2026 revenue outlook | Growth of up to 10% |
The balance sheet remains important. Moderna reported a loss of roughly $0.8 billion in the second quarter. Executives project that year-end cash will total between $4.7 billion and $5.2 billion.
Risks: Intismeran has not received regulatory approval, and comprehensive Phase 3 data have yet to be made public. The personalized nature of manufacturing could drive up expenses. Should the hazard ratio prove less robust, release be postponed, or if approval is limited in scope, some of the platform’s premium may be at risk.
The U.S. market resumes trading on Thursday at 09:30 EDT. Investors are focusing on analyst updates, a key medical conference date, and regulatory input. These factors will be crucial in deciding if Wednesday’s rally remains intact.
Related articles: NASDAQ:MRNA
One trial reset the price. The evidence now has to catch up.
Market data: August 19, 2026 close, 16:00 EDT
Prepared after the U.S. session
Highest close in about three years
Phase 3 melanoma readout
One session, Financial Times estimate
Close × 399.24M shares
The re-rating in one picture
Investor read: the market priced a platform, not just a melanoma product. The $44 billion value gain equals about 14.7× Barclays’ $3 billion estimate for 2035 melanoma sales.
What Phase 3 proved — and did not
INTerpath-001 enrolled 1,137 patients with resected stage IIB-IV melanoma. No new safety signal was reported.
Pre-readout targets now sit below the tape
| Firm | View | Target |
|---|---|---|
| Piper Sandler | Overweight | $77 |
| Goldman Sachs | Neutral | $67 |
| Citigroup | Neutral | $60 |
| RBC Capital | Sector Perform | $45 |
| Wolfe Research | Underperform | $25 |
The $174.38 close is 126% above the old high target and 243% above the $50.84 consensus. These targets have not absorbed the trial result.
Cash runway versus the new oncology premium
Bars share a $44 billion scale. The sales figure is an analyst estimate for melanoma in 2035, not company guidance.
Near-term checkpoints
| Next U.S. session | August 20, 09:30 EDT |
| Analyst model resets | Watch targets and probability assumptions |
| Medical presentation | Date not yet disclosed |
| Regulatory path | Companies are already in discussions |
| Possible availability | 2027, subject to approval |
